2 results about "Streptococcus hemolyticus" patented technology

The invention discloses bacillus licheniformis YL-001 with anti-inflammatory and antibacterial effects and application of the bacillus licheniformis YL-001, and belongs to the technical field of biology, and the bacillus licheniformis YL-001 is separated from soil. The preservation number of the bacillus licheniformis strain is GDMCC (China General Microbiological Culture Collection Center) No.66556. A metabolite of the bacillus licheniformis YL-001 provided by the invention has obvious capabilities of inhibiting secretion of inflammatory factors and inhibiting growth of streptococcus pneumoniae and beta hemolytic streptococcus, and can improve the total antioxidant capacity of serum, and the strain is good in biocompatibility, high in safety and suitable for industrial production. The method has important significance for developing anti-inflammatory or bacteriostatic medicines, health care products and foods, and is particularly suitable for preparing products with the sore-throat relieving effect.

This invention belongs to the field of functional probiotic screening and application technology, specifically involving a novel strain of *Lactobacillus plantarum* (…). Lactiplantibacillus plantarum The *Lactobacillus plantarum* strain was deposited on January 15, 2026, at the China Center for Type Culture Collection (CCTCC), Wuhan University, Wuhan, China, with accession number CCTCC NO: M202026133. This strain exhibits strong antioxidant capacity, significant inhibitory and flocculating effects against hemolytic streptococci, and can significantly reduce the levels of pro-inflammatory cytokines IL-6 and IL-1β induced by hemolytic streptococci while increasing the level of the anti-inflammatory cytokine IL-22. It has no toxic effects on the body, good safety profile, and can be used to prevent colonic polyps and colon cancer caused by hemolytic streptococci, showing broad application prospects.